[go: up one dir, main page]

RU2001119056A - Modulation of the immune response using ribavirin - Google Patents

Modulation of the immune response using ribavirin

Info

Publication number
RU2001119056A
RU2001119056A RU2001119056/14A RU2001119056A RU2001119056A RU 2001119056 A RU2001119056 A RU 2001119056A RU 2001119056/14 A RU2001119056/14 A RU 2001119056/14A RU 2001119056 A RU2001119056 A RU 2001119056A RU 2001119056 A RU2001119056 A RU 2001119056A
Authority
RU
Russia
Prior art keywords
stimulus
nucleoside
ribavirin
molecular marker
allergen
Prior art date
Application number
RU2001119056/14A
Other languages
Russian (ru)
Other versions
RU2211698C2 (en
Inventor
Роберт Тэм
Original Assignee
Ай-Си-Эн Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ай-Си-Эн Фармасьютикалз, Инк. filed Critical Ай-Си-Эн Фармасьютикалз, Инк.
Publication of RU2001119056A publication Critical patent/RU2001119056A/en
Application granted granted Critical
Publication of RU2211698C2 publication Critical patent/RU2211698C2/en

Links

Claims (16)

1. Способ модулирования ответа иммунной системы на стимул, при котором: коррелируют стимул с воздействием на В7 маркер; коррелируют применение нуклеозида в пределах диапазона концентраций с модуляцией В7 молекулярного маркера, которая является обратной этому воздействию; и представляют иммунной системе нуклеозид в пределах этого диапазона концентраций.1. A method of modulating the response of the immune system to a stimulus, in which: the stimulus is correlated with the effect on the B7 marker; correlate the use of nucleoside within the concentration range with modulation of the B7 molecular marker, which is the inverse of this effect; and present the nucleoside to the immune system within this concentration range. 2. Способ по п.1, где стимул представляет собой аллерген.2. The method according to claim 1, where the stimulus is an allergen. 3. Способ по п.1, где стимул представляет собой новообразование.3. The method according to claim 1, where the stimulus is a neoplasm. 4. Способ по п.1, где стимул представляет собой вирус.4. The method according to claim 1, where the stimulus is a virus. 5. Способ по п.1, где стимул представляет собой бактерию.5. The method according to claim 1, where the stimulus is a bacterium. 6. Способ по п.1, где стимул представляет собой инвазию.6. The method according to claim 1, where the stimulus is an invasion. 7. Способ по п.1, где стимул представляет собой аутоиммунную реакцию.7. The method according to claim 1, where the stimulus is an autoimmune reaction. 8. Способ по любому из пп.1-7, где молекулярный маркер представляет собой В7-1.8. The method according to any one of claims 1 to 7, where the molecular marker is a B7-1. 9. Способ по любому из пп.1-8, где молекулярный маркер представляет собой В7-2.9. The method according to any one of claims 1 to 8, where the molecular marker is a B7-2. 10. Способ по любому из пп.1-8, где нуклеозид является рибавирином.10. The method according to any one of claims 1 to 8, where the nucleoside is ribavirin. 11. Способ по любому из пп.1-8, где нуклеозид является аналогом рибавирина.11. The method according to any one of claims 1 to 8, where the nucleoside is an analogue of ribavirin. 12. Способ по п.1, где стимул выбран из группы, состоящей из аллергена, микроба, новообразования, инвазии и аутоиммунной реакции, молекулярный маркер представляет собой В7-1, а нуклеозид является рибавирином.12. The method according to claim 1, where the stimulus is selected from the group consisting of an allergen, microbe, neoplasm, invasion and autoimmune reaction, the molecular marker is B7-1, and the nucleoside is ribavirin. 13. Способ по п.1, где стимул выбран из группы, состоящей из аллергена, микроба, новообразования, инвазии и аутоиммунной реакции, молекулярный маркер представляет собой В7-2, а нуклеозид является рибавирином.13. The method according to claim 1, where the stimulus is selected from the group consisting of allergen, microbe, neoplasm, invasion and autoimmune reaction, the molecular marker is B7-2, and the nucleoside is ribavirin. 14. Способ по п.1, где стимул выбран из группы, состоящей из аллергена, микроба, новообразования, инвазии и аутоиммунной реакции, молекулярный маркер представляет собой В7-1, а нуклеозид не является рибавирином.14. The method according to claim 1, where the stimulus is selected from the group consisting of allergen, microbe, neoplasm, invasion and autoimmune reaction, the molecular marker is B7-1, and the nucleoside is not ribavirin. 15. Способ по любому из пп.12-14, при котором диапазон концентраций составляет между приблизительно 0,2 мкМ и приблизительно 5 мкМ, соответственно, в текучей среде, содержащей клетки, экспрессирующие В7 маркер.15. The method according to any one of claims 12-14, wherein the concentration range is between about 0.2 μM and about 5 μM, respectively, in a fluid containing cells expressing a B7 marker. 16. Способ по любому из пп.1-8, при котором дополнительно коррелируют стимул с повышением ответа типа 2, и коррелируют применение нуклеозида с понижением ответа типа 2.16. The method according to any one of claims 1 to 8, wherein the stimulus is additionally correlated with an increase in type 2 response, and the use of a nucleoside is correlated with a decrease in type 2 response.
RU2001119056/14A 1999-01-29 1999-12-20 Modulation of immune response due to ribavirin RU2211698C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24136799A 1999-01-29 1999-01-29
US09/241,367 1999-01-29

Publications (2)

Publication Number Publication Date
RU2001119056A true RU2001119056A (en) 2003-06-27
RU2211698C2 RU2211698C2 (en) 2003-09-10

Family

ID=22910442

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001119056/14A RU2211698C2 (en) 1999-01-29 1999-12-20 Modulation of immune response due to ribavirin

Country Status (20)

Country Link
EP (1) EP1146883A4 (en)
JP (1) JP2002535371A (en)
KR (1) KR20020023939A (en)
CN (1) CN1334736A (en)
AU (1) AU2483300A (en)
BR (1) BR9917090A (en)
CA (1) CA2357735A1 (en)
CZ (1) CZ20012519A3 (en)
HK (1) HK1040937A1 (en)
HR (1) HRP20010496A2 (en)
HU (1) HUP0200027A2 (en)
IL (1) IL144130A0 (en)
MX (1) MXPA01007211A (en)
NO (1) NO20013529L (en)
PL (1) PL364699A1 (en)
RU (1) RU2211698C2 (en)
SI (1) SI20802A (en)
SK (1) SK10092001A3 (en)
WO (1) WO2000044388A1 (en)
ZA (1) ZA200105595B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290178A1 (en) 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
RU2286172C2 (en) 2000-08-17 2006-10-27 Трипеп Аб Ribavirin-containing vaccines and methods for their application
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
SE534514C2 (en) * 2006-03-14 2011-09-20 Wholesome Biopharm Pty Ltd Composition for the treatment of allergic diseases
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0038629A1 (en) * 1980-04-17 1981-10-28 Beecham Group Plc Virazole derivatives, process for their preparation and use as antiviral agents
BE902199A (en) * 1984-10-29 1985-07-31 Vira Tek Inc METHOD OF MEDICAL TREATMENT OF VIRAL DISEASES USING 1-BETA-D-RIBOFURANNOSYL-1, 2,4-TRIAZOLE-3-CARBOXAMIDE.
AU5668886A (en) * 1986-03-27 1987-10-20 Harry Edward Gruber A method of increasing adenosine excretion
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
RU2088232C1 (en) * 1995-02-14 1997-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Inhibitor of marburg virus reproduction
IL125088A0 (en) * 1996-01-23 1999-01-26 Icn Pharmaceuticals Modulation of TH1/TH2 cytokine expression
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JP2002503212A (en) * 1996-10-16 2002-01-29 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド Monocyclic nucleosides, analogs and uses thereof

Similar Documents

Publication Publication Date Title
BR0209552A (en) Animal immunity modulation device
WO2003020161A3 (en) Immune modulation device for use in animals
ID29997A (en) AFINITY MEMBRANE SYSTEM AND ITS USE METHOD (Fraction from P-972101)
DE69637969D1 (en) GENERATION OF HUMAN CYTOTOXIC T CELLS, GENES OF CARCINOMES, AND ITS APPLICATIONS
BG101103A (en) THEMOMERASIS IN MAMMALIA
TR199901572T2 (en) Transdermal therapeutic system.
DE3762867D1 (en) MESOMORPHER POLYMER ACTIVE SUBSTANCE, USABLE FOR NONLINEAR OPTICS.
ES2077040T3 (en) FUNCTIONAL FLUIDS.
DE69232782D1 (en) Targeted introduction of a virus vector into mammalian cells.
NO982370D0 (en) Catalyst carrier where cation-forming activator is bound to carrier
BR0013391A (en) Use of the baff receptor (bcma) as an immunoregulatory agent
RU94031166A (en) Method of preparing sequence copies, vessel, device, carrier, method of preparing thereof, and testing procedure
ATE541039T1 (en) IMMUNO-STIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
EP0840747A4 (en) PAPILLOMAVIRUS POLYPROTEIN CONSTRUCTS
RU2001119056A (en) Modulation of the immune response using ribavirin
DK1228107T3 (en) Acrylic block copolymer pigment dispersants containing heterocyclic groups
EP0523140A4 (en) Reagents and methods for modulating gene expression through rna mimicry
NO983372D0 (en) Modulation of TH1 / TH2 cytokine expression of ribavirin and ribavirin analogs in activated T lymphocytes
PL324198A1 (en) Composition containing at least one grafted silicone polymer and t least and at least one thickening polymer or (meth) acrylamide or (meth) acrylamide derivative copolymer for trating creatine substances and their application
EP0629033A3 (en) Device using solar cells.
ES2114335T3 (en) CATALYST SYSTEMS OF THE CATALYST TYPE OF ZIEGLER-NATTA.
DE59101233D1 (en) Retaining clip for fastening components to carrier plates.
FR2769316B1 (en) COPOLYMER GRAFTED BY RADICAL POLYMERIZATION IN THE PRESENCE OF STABLE RADICALS, ITS PREPARATION AND ITS APPLICATIONS
HK1040937A1 (en) Modulation of immune response by ribavirin
DE69119097D1 (en) Activation of polysaccharide hydrolase